Hyperactive neutrophil chemotaxis contributes to anti-tumor necrosis factor-α treatment resistance in inflammatory bowel disease.

Tung On Yau Jayakumar Vadakekolathu Gemma Ann Foulds Guodong Du Benjamin Dickins Christos Polytarchou Sergio Rutella

Published in: Journal of gastroenterology and hepatology (2022)

Hyperactive neutrophil chemotaxis influences responses to anti-TNF-α treatment, and IL13RA2 is a potential biomarker to predict anti-TNF-α treatment response.

Keyphrases

rheumatoid arthritis
combination therapy
systemic lupus erythematosus